Effects of pitavastatin in hypercholesterolemic patients with chronic obstructive pulmonary disease (COPD)

Mamoru Shiga; Naoaki Ban; Kazunobu Kuwabara; Hideharu Hata; Daishuke Ohira; Toshinori Nasu; Mashahiro Hiroshe; Rieko Kondou; Takahiko Horiguchi

Effects of pitavastatin in hypercholesterolemic patients with chronic obstructive pulmonary disease (COPD)

Mamoru Shiga, Naoaki Ban, Kazunobu Kuwabara, Hideharu Hata, Daishuke Ohira, Toshinori Nasu, Mashahiro Hiroshe, Rieko Kondou, Takahiko Horiguchi

Research output: Contribution to journal › Article › peer-review

Abstract

Objective : COPD is recognized as systemic inflammation, and statin-use has been reported to be associated with better prognosis in COPD. The objective of this study was to investigate the effects of pitavastatin in hypercholesterolemic patients with COPD. Methods : Twenty six outpatient hypercholesterolemic patients with COPD [forced expiratory volume in 1 second (FEV₁) >50%) who provided informed consent were enrolled. Inflammatory markers were measured before and 12 weeks after enrollment. Result and Conclusion : Pitavastatin significantly decreased hs-CRP after 12 weeks (2778.8 ± 4713.9 ng/ ml, 1035.9 ± 1598.7 ng/ml, p = 0.0083). Pitavastatin is suggested to improve systemic inflammation in hypercholesterolemic patients with COPD.

Original language	English
Pages (from-to)	1254-1260
Number of pages	7
Journal	Japanese Journal of Chest Diseases
Volume	71
Issue number	12
Publication status	Published - 2012

All Science Journal Classification (ASJC) codes

Pulmonary and Respiratory Medicine

Cite this

@article{1d42a5d11f9e482da8b278601d7cac91,

title = "Effects of pitavastatin in hypercholesterolemic patients with chronic obstructive pulmonary disease (COPD)",

abstract = "Objective : COPD is recognized as systemic inflammation, and statin-use has been reported to be associated with better prognosis in COPD. The objective of this study was to investigate the effects of pitavastatin in hypercholesterolemic patients with COPD. Methods : Twenty six outpatient hypercholesterolemic patients with COPD [forced expiratory volume in 1 second (FEV1) >50%) who provided informed consent were enrolled. Inflammatory markers were measured before and 12 weeks after enrollment. Result and Conclusion : Pitavastatin significantly decreased hs-CRP after 12 weeks (2778.8 ± 4713.9 ng/ ml, 1035.9 ± 1598.7 ng/ml, p = 0.0083). Pitavastatin is suggested to improve systemic inflammation in hypercholesterolemic patients with COPD.",

author = "Mamoru Shiga and Naoaki Ban and Kazunobu Kuwabara and Hideharu Hata and Daishuke Ohira and Toshinori Nasu and Mashahiro Hiroshe and Rieko Kondou and Takahiko Horiguchi",

year = "2012",

language = "English",

volume = "71",

pages = "1254--1260",

journal = "Japanese Journal of Chest Diseases",

issn = "0385-3667",

publisher = "Kokuseido Publishing Co. Ltd",

number = "12",

}

TY - JOUR

T1 - Effects of pitavastatin in hypercholesterolemic patients with chronic obstructive pulmonary disease (COPD)

AU - Shiga, Mamoru

AU - Ban, Naoaki

AU - Kuwabara, Kazunobu

AU - Hata, Hideharu

AU - Ohira, Daishuke

AU - Nasu, Toshinori

AU - Hiroshe, Mashahiro

AU - Kondou, Rieko

AU - Horiguchi, Takahiko

PY - 2012

Y1 - 2012

N2 - Objective : COPD is recognized as systemic inflammation, and statin-use has been reported to be associated with better prognosis in COPD. The objective of this study was to investigate the effects of pitavastatin in hypercholesterolemic patients with COPD. Methods : Twenty six outpatient hypercholesterolemic patients with COPD [forced expiratory volume in 1 second (FEV1) >50%) who provided informed consent were enrolled. Inflammatory markers were measured before and 12 weeks after enrollment. Result and Conclusion : Pitavastatin significantly decreased hs-CRP after 12 weeks (2778.8 ± 4713.9 ng/ ml, 1035.9 ± 1598.7 ng/ml, p = 0.0083). Pitavastatin is suggested to improve systemic inflammation in hypercholesterolemic patients with COPD.

AB - Objective : COPD is recognized as systemic inflammation, and statin-use has been reported to be associated with better prognosis in COPD. The objective of this study was to investigate the effects of pitavastatin in hypercholesterolemic patients with COPD. Methods : Twenty six outpatient hypercholesterolemic patients with COPD [forced expiratory volume in 1 second (FEV1) >50%) who provided informed consent were enrolled. Inflammatory markers were measured before and 12 weeks after enrollment. Result and Conclusion : Pitavastatin significantly decreased hs-CRP after 12 weeks (2778.8 ± 4713.9 ng/ ml, 1035.9 ± 1598.7 ng/ml, p = 0.0083). Pitavastatin is suggested to improve systemic inflammation in hypercholesterolemic patients with COPD.

UR - http://www.scopus.com/inward/record.url?scp=84871435003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871435003&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84871435003

SN - 0385-3667

VL - 71

SP - 1254

EP - 1260

JO - Japanese Journal of Chest Diseases

JF - Japanese Journal of Chest Diseases

IS - 12

ER -

Effects of pitavastatin in hypercholesterolemic patients with chronic obstructive pulmonary disease (COPD)

Abstract

All Science Journal Classification (ASJC) codes

Other files and links

Fingerprint

Cite this